Serumski cistatin C kao biomarker kod ne-Hodgkinovog limfoma i njegova povezanost sa aktivnošću paraoksonaze 1

  • Bosa Mirjanić-Аzaric Katedra za medicinsku biohemiju, Medicinski fakultet, Univerzitet u Banjoj Luci, Banja Luka, Republika Srpska, Bosna i Hercegovina
  • Smiljana Mijic Aqualab laboratorija, Banja Luka, Republika Srpska
  • Žana Radić Savić Katedra za medicinsku biohemiju, Medicinski fakultet , Univerzitet u Banja Luci, Republika Srpska
  • Siniša Stanković Medicinski fakultet, Univerzitet u Banjoj Luci, Republika Srpska
  • Dragana Malčić-Zanić Medicinski fakultet, Univerzitet u Banjoj Luci, Republika Srpska
  • Nataša Mihailović Egeljić Medicinski fakultet, Univerzitet u Banjoj Luci, Republika Srpska
  • Đorđe Stojisavljević Medicinski fakultet, Univerzitet u Banjoj Luci, Republika Srpska
  • Bojana Ivetić Institut za medicinsku biohemiju, Univerzitetski klinički centar Republike Srpske, Banja Luka
  • Nataša Bogavac-Stanojević Katedra za medicinsku biohemiju, Univerzitet u Beogradu-Fakultet za farmaciju
DOI: https://doi.org/10.5937/jomb0-61502
Ključne reči: cistatin C, paraoksonaza 1, ne-Hodgkinov limfom

Sažetak


Uvod: Cilj ove pilot studije bio je da se proceni potencijal cistatina C (Cys C) kao biomarkera kod ne-Hodgkinovog limfoma (NHL) i ispita njegova povezanost sa aktivnošću paraoksonaze 1 (PON1).

Metode: Studija je obuhvatila 44 pacijenta sa B-ćelijskim NHL i 44 zdrava ispitanika. Cys C je meren pomoću analizatora Cobas e 801 (Roche Diagnostics GmbH, Mannheim, Nemačka), dok su PON1 i ukupni antioksidativni status (TAS) mereni na sistemu ILab 300+ (Instrumentation Laboratory, Milano, Italija).

Rezultati: Serumski nivo Cys C (mg/L) bio je značajno viši kod pacijenata sa NHL u poređenju sa kontrolnom grupom: 1,03 (0,88–1,24) naspram 0,83 (0,78–0,90), P < 0,001. Dijagnostička sposobnost Cys C, procenjena preko površine ispod ROC krive (AUC), iznosila je 0,812 (95% CI: 0,732–0,902). Optimalna granična vrednost za Cys C bila je 0,870 mg/L, sa osetljivošću i specifičnošću od 77,1% i 75,6%. Značajna negativna korelacija je primećena između Cys C i aktivnosti PON1 (r = –0,42, P = 0,010) kod pacijenata sa NHL.

Zaključci: Ova studija ističe potencijal Cys C kao biomarkera kod NHL. U multivarijabilnoj analizi, Cys C je ostao jedini značajan prediktor bolesti, pri čemu svaka jedinica povećanja odgovara približno trostrukom povećanju verovatnoće za NHL. Negativna korelacija između Cys C i PON1, primećena po prvi put kod pacijenata sa NHL, može pružiti važne smernice za buduća istraživanja molekularnih mehanizama koji stoje iza ove bolesti.

 

Reference

1. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Critical Reviews in Clinical Laboratory Sciences 2004; 41(5–6): 467-550.
2. Fernando S, Polkinghorne KR. Cystatin C: not just a marker of kidney function. J Bras Nefrol 2020; 42 (1):6-7.
3. Breznik B, Mitrović A, T Lah T, Kos J. Cystatins in cancer progression: More than just cathepsin inhibitors. Biochimie 2019; 166:233-250.
4. Huang C, Lu J, Yang J, Wang Z, Hang D, Fu Z. Associations of serum cystatin C concentrations with total mortality and mortality of 12 site-specific cancers. Front Oncol 2024; 14:1405879.
5. Corbeanu R.I, Găman A.M. The Involvement of Oxidative Stress in Non-Hodgkin’s Lymphomas; A Review of the Literature. J Mind Med Sci 2022; 9(1): 1-15.
6. Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012; 4(11):523-32.
7. Vavlukis M, Vavlukis A, Krsteva K, Topuzovska S. Paraoxonase 1 gene polymorphisms in lipid oxidation and atherosclerosis development. Front Genet 2022; 13:966413.
8. Mirjanic-Azaric B, Stankovic S, Nezic L, Radic Savic Z, Malcic-Zanic D, Skrbic R, et al. Analysis of redox status and HDL sublasses in patients with lymphoma and the associations with FDG-PET/CT findings. Front Oncol 2023; 13:1221414.
9. Mugnaini E.N, Ghosh N. Lymphoma. Prim Care 2016; 43(4): 661–75.
10. Mengting Z, Yuekang X. Involvement of cystatin C in immunity and apoptosis. Immunol Lett 2018; 196:80-90.
11. Leto G, Crescimanno M, Flandina C. On the role of cystatin C in cancer progression. Life Sci 2018; 202:152-160.
12. Richter R, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9(6):745-53.
13. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37(4):277-85.
14. Mirjanić-Azarić B, Stanković S, Radić Savić Z, Malčić Zanić D, Ninić A, Vuković M, et al. Assessment of the diagnostic value of serum cathepsin S and its correlation with HDL subclasses in patients with Non-Hodgkin’s lymphoma. J Med Biochem 2024; 43(5):711-9.
15. Hammouda NE, Salah El-Din MA, El-Shishtawy MM, El-Gayar AM. Serum cystatin C as a biomarker in diffuse large B-Cell lymphoma. Sci Pharm 2017; 85(1):9.
16. Nishio C, Yoshida K, Nishiyama K, Hatanaka H, Yamada M. Involvement of cystatin C in oxidative stress induced apoptosis of cultured rat CNS neurons. Brain Res 2000; 873(2): 252-62.
17. Softić A, Begić L, Halilbasić A, Kos J. Cystatin C in sera of patients with aggressive non-Hodgkin B-cell lymphoma. Med Glas (Zenica) 2011; 8(1):97-100.
18. Balci H, Genc H, Papila C, Can G, Papila B, Yanardag H, et al. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin Lab Anal 2012; 26 (3):155-60.
19. Özdemir Başer Ö, Göçmen AY, Aydoğan Kırmızı D. The role of inflammation, oxidation and Cystatin C in the pathophysiology of polycystic ovary syndrome. Turk J Obstet Gynecol 2022; 19(3):229-35.
20. Varga E, Seres I, Harangi M, Sztanek F, Asztalos L, Lõcsey L, et al. Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. Dis Markers 2009; 26(3):141-8.
21. Zi M, Xu Y. Involvement of cystatin C in immunity and apoptosis. Immunol Lett 2018; 196:80-90.
22. Lu S, Li S. Association between preoperative serum Cystatin C levels and postsurgical
oncological prognosis in patients with PRCC: A retrospective cohort study. Cancer Med 2022; 11(22):4112-21.
23. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000; 80(3):1107–213.
24. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol 2018; 217(6):1915–28.
25. Bojic S, Kotur-Stevuljevic J, Kalezic N, Jelic-Ivanovic Z, Stefanovic A, Palibrk I, et al. Low paraoxonase 1 activity predicts mortality in surgical patients with sepsis. Dis Markers 2014:2014:427378.
26. Jozanov-Stankov O, Đuric J, Dobutovic B, Isenovic E. Determination of total antioxidant status (TAS) as a biochemical parameter in control of workers' health. Arch Biol Sci 2009; 61(3): 375-82.
Objavljeno
2026/03/03
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2026 Bosa Mirjanić-Аzaric, Smiljana Mijic, Zana Radic Savic, Sinisa Stankovic, Dragana Malcic-Zanic, Natasa Mihailovic Egeljic, Đorđe Stojisavljevic, Bojana ivetic, Natasa Bogavac-Stanojevic

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.